Arvinas (ARVN) Income towards Parent Company (2017 - 2026)
Arvinas (ARVN) posted quarterly Income towards Parent Company of -$57.6 million for Q1 2026, down 169.48% year-over-year from $82.9 million in Q1 2025, and up 14.54% quarter-over-quarter from -$67.4 million in Q4 2025.
Arvinas (ARVN) Income towards Parent Company (2017 - 2026) Analysis & Trends
Arvinas' Income towards Parent Company history runs 10 years deep, the most recent figure standing at -$57.6 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 169.48% year-over-year to -$57.6 million; the TTM figure through Mar 2026 stood at -$221.3 million (down 374.89% YoY), while the FY2025 annual figure was -$80.8 million, up 59.38% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$57.6 million, up from -$67.4 million in the prior quarter.
- The five-year high for Income towards Parent Company was $82.9 million in Q1 2025, with the low at -$154.8 million in Q4 2023.
- The 5-year median for Income towards Parent Company is -$63.3 million (2022), against an average of -$57.3 million.
- The sharpest annual moves came in 2025 and 2026: Income towards Parent Company surged 219.45% in 2025, then plunged 169.48% in 2026.
- Arvinas' Income towards Parent Company stood at -$80.1 million in 2022, then tumbled by 93.26% to -$154.8 million in 2023, then soared by 70.87% to -$45.1 million in 2024, then sank by 49.45% to -$67.4 million in 2025, then gained by 14.54% to -$57.6 million in 2026.
- Business Quant data shows ARVN's Income towards Parent Company at -$57.6 million in Q1 2026, -$67.4 million in Q4 2025, and -$35.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 169.40 Mn |
| Mar 31, 2026 | -57.60 Mn |
| Dec 31, 2025 | -67.40 Mn |
| Sep 30, 2025 | -35.10 Mn |
| Jun 30, 2025 | -61.20 Mn |
| Mar 31, 2025 | 82.90 Mn |
| Dec 31, 2024 | -45.10 Mn |
| Sep 30, 2024 | -49.20 Mn |
| Jun 30, 2024 | -35.20 Mn |
| Mar 31, 2024 | -69.40 Mn |
| Dec 31, 2023 | -154.80 Mn |
| Sep 30, 2023 | -63.90 Mn |
| Jun 30, 2023 | -65.30 Mn |
| Mar 31, 2023 | -80.80 Mn |
| Dec 31, 2022 | -80.10 Mn |
| Sep 30, 2022 | -63.30 Mn |
| Jun 30, 2022 | -67.50 Mn |
| Mar 31, 2022 | -61.10 Mn |
| Dec 31, 2021 | -46.10 Mn |
| Sep 30, 2021 | -46.80 Mn |